en · de · es · fr · pt
peptide-index.peptides9002.com › Info › Stability, Handling, And Analytical Control — Worked Examples

Stability, Handling, And Analytical Control — Worked Examples

By Editorial Desk · published 2025-12-23 · last reviewed 2026-01-10 · Info

This is a working overview of electrospray ionization, written for readers who want more than a one-paragraph summary but less than a textbook.

Reviewed 2026-01-10. Anything still debated is marked as such rather than presented as settled.

Stability, Handling, and Analytical Control

Lyophilised material kept dry at minus 20 degrees Celsius or colder is the most stable form, and suppliers commonly state a shelf life of two years or more under those conditions. Once dissolved, degradation accelerates through hydrolysis and deamidation, particularly at alkaline pH or elevated temperature. Working solutions are usually divided into single-use aliquots to avoid repeated freeze-thaw cycles. The choice of reconstitution solvent affects both stability and the ionic strength of the final preparation.

Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres is the standard purity method. Mass spectrometry, typically electrospray ionisation, confirms identity through the expected mass-to-charge pattern. Amino acid analysis can verify composition independently. Chiral purity requires separate techniques such as derivatisation followed by chromatographic separation, and such data are rarely reported for research-grade material.

Analytical Methods and Handling

Solubility behavior is a practical concern for handling. Selank dissolves readily in water and in common aqueous buffers, which simplifies preparation of working solutions. The choice of solvent, ionic strength, and pH can influence aggregation over time, particularly at higher concentrations. Aqueous solutions are typically sterile-filtered before use. Because stability depends on several variables, storage and handling notes should be treated as general guidance rather than fixed rules, and specific values are best confirmed against a certificate of analysis for each batch.

Characterization of Selank in a laboratory setting relies on standard peptide methods. Reverse-phase high-performance liquid chromatography separates the target from related impurities and provides a purity figure, commonly reported as 95 percent or higher. Mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, confirms the molecular mass and helps detect truncation or modification. Amino acid analysis can verify composition when a sequence-level check is needed. These techniques together establish identity and purity for a given lot.

Selank at a glance

PropertyValueNotes
Dry storage temperature-20 C or belowSealed, desiccated, protected from light
Solution stabilityHours to days at 2-8 CDepends on buffer and microbial load
Preferred pH rangeNear neutral to slightly acidicAlkaline pH accelerates hydrolysis
Main degradation routesHydrolysis and deamidationNo cysteine or methionine in sequence
Identity confirmationElectrospray mass spectrometryObserved mass compared with 751.9 Da

Background and Peptide Identity

Reported activity for Selank centers on anxiolytic and nootropic effects. Russian clinical reports describe use in anxiety and in cognitive or attention-related complaints. Most of this evidence comes from studies conducted by the same research groups that developed the peptide. Independent replication in other countries remains limited, and no major Western regulatory agency has approved the compound for any indication. The gap between local reports and external verification is a recurring point in discussions of the peptide.

Tuftsin, the parent structure, is a naturally occurring immunomodulatory tetrapeptide released from the Fc region of immunoglobulin G by spleen enzymes. Selank extends this four-residue sequence with three additional amino acids. The stated rationale is that the added tail slows enzymatic breakdown and may influence receptor interactions. How the full heptapeptide behaves at the molecular level is not firmly established, and proposed mechanisms often involve indirect modulation of neurotransmitter or immune signaling rather than a single defined target.

Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.

Related pages on this site

Administration, Testing and Availability

Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.

Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.

Identity and Structural Background

Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.

Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.

Analytical Methods and Stability

Handling follows standard practice for research peptides. Material is weighed in a low-humidity environment because the powder absorbs atmospheric moisture. Purity is reported as the percentage area of the main peak in a chromatogram, with specifications commonly set at 95 percent or higher; values below that threshold indicate the presence of truncated or modified species. Residual trifluoroacetate from purification is often present and may affect mass balance. Certificates of analysis should state the analytical method, the column and gradient used, and the lot-specific retention time so that results can be compared across suppliers.

Identity and purity of selank are established with reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The peptide elutes from C18 columns with acetonitrile gradients in water containing trifluoroacetic acid or formic acid, and detection is usually performed by ultraviolet absorbance near 214 nm. Electrospray ionization in positive mode gives a doubly protonated ion near m/z 377, consistent with a mass of about 752 Da. Amino acid analysis or tandem mass spectrometry of fragment ions confirms the sequence. Because the molecule has no aromatic residues, it lacks a usable 280 nm chromophore, so low-wavelength detection or mass spectrometry is required.

Notes from published material

== Awards == The society sponsors several awards including the Curt Brunnée Award for achievements in instrumentation by a scientist under 45 years of age, the Thomson Medal Award for achievements in mass spectrometry, as well as travel awards and student paper awards:

== Discovery == By the mid-1960s, it had become apparent from pharmacologic studies that opioids were likely to exert their actions at specific receptor sites, and that there were likely to be multiple such sites. Early studies had indicated that opiates appeared to accumulate in the brain. The receptors were first identified as specific molecules through the use of binding studies, in which opiates that had been labeled with radioisotopes were found to bind to brain membrane homogenates. The first such study was published in 1971, using 3H-levorphanol. In 1973, Candace Pert and Solomon H. Snyder published the first detailed binding study of what would turn out to be the μ opioid receptor, using 3H-naloxone. That study has been widely credited as the first definitive finding of an opioid receptor, although two other studies followed shortly after.

=== Hopman Cup === Zverev represented Germany at the Hopman Cup for four consecutive years from 2016 through 2019 with three different partners. In 2016, he competed with Sabine Lisicki. The duo won their tie against the French team, with Zverev winning both his singles and mixed doubles matches. However, they were shut out against Great Britain and Australia Green and did not advance to the final. The following year, he entered the competition with Andrea Petkovic. While the pair only won their tie against Great Britain, Zverev also defeated Federer in singles in his first tournament back from injury. Zverev enjoyed more success in 2018 and 2019, pairing with Angelique Kerber. In their first year together, they advanced to the final, primarily on the strength of the pair winning all three of their mixed doubles matches. In the final against Switzerland, Zverev lost his singles match to Federer. Although Kerber won her singles match against Belinda Bencic, they lost the decisive mixed doubles rubber. They returned in 2019 and again reached the final to set up a rematch of the previous year's final with Federer and Bencic. In a round-robin group with Australia, France, and Spain, the two of them won all six of their singles matches, but lost two of their three mixed doubles matches against Australia and France. Like the previous year, the final was decided by the mixed doubles match after Federer defeated Zverev and Kerber defeated Bencic. With the Fast4 format, the match went to three sets. In the third set tiebreak, both teams had a match point at 4–4.

== Research directions == Research into the mechanism of HD is focused on identifying the functioning of Htt, how mHtt differs or interferes with it, and the brain pathology that the disease produces. Research is conducted using in vitro methods, genetically modified animals, (also called transgenic animal models), and human volunteers. Animal models are critical for understanding the fundamental mechanisms causing the disease, and for supporting the early stages of drug development. The identification of the causative gene has enabled the development of many genetically modified organisms including nematodes (roundworms), Drosophila fruit flies, and genetically modified mammals including mice, rats, sheep, pigs and monkeys that express mutant huntingtin and develop progressive neurodegeneration and HD-like symptoms. Research is being conducted using many approaches to either prevent HD or slow its progression. Disease-modifying strategies can be broadly grouped into three categories: reducing the level of the mutant huntingtin protein (including gene splicing and gene silencing); approaches aimed at improving neuronal survival by reducing the harm caused by the protein to specific cellular pathways and mechanisms (including protein homeostasis and histone deacetylase inhibition); and strategies to replace lost neurons. In addition, novel therapies to improve brain functioning are under development; these seek to produce symptomatic rather than disease-modifying therapies, and include phosphodiesterase inhibitors.

Since 2009, Carrey's work has included a leading role in Glenn Ficarra and John Requa's I Love You Phillip Morris, premiering in January 2009 at the Sundance Film Festival before receiving a wide release in February 2010. Carrey portrayed Steven Jay Russell, a con artist, imposter, and multiple prison escapee who falls in love with his fellow inmate, Phillip Morris (played by Ewan McGregor). The film received largely positive reviews, with Damon Wise of The Times giving the film four stars out of five, stating, "I Love You Phillip Morris is an extraordinary film that serves as a reminder of just how good Carrey can be when he's not tied into a generic Hollywood crowd-pleaser. His comic timing remains as exquisite as ever." For the first time in his career, Carrey portrayed multiple characters in Disney's 3D animated take on the classic Charles Dickens tale, A Christmas Carol (2009), voicing Ebenezer Scrooge and the Ghosts of Christmas Past, Present, and Future. Directed by Robert Zemeckis, the film also starred Robin Wright Penn, Bob Hoskins, Colin Firth, Gary Oldman, and Cary Elwes. The film received decent reviews and was a financial success. Carrey landed the lead role in Mr. Popper's Penguins (2011), playing Tom Popper Jr., a realtor who becomes the caretaker of a family of penguins. The film received a mixed reception upon release.

Sources: en.wikipedia.org

Further detail

PT-00114, also known as TCAP-1, is a corticotropin-releasing hormone (CRH) inhibitor which is under development for the treatment of generalized anxiety disorder, major depressive disorder, opioid-related disorders, post-traumatic stress disorder (PTSD), and mood disorders. It is taken by subcutaneous injection. The drug is a synthetic analogue of the teneurin C-terminal associated peptides (TCAP) and is a 41-amino acid peptide. It has been reported to produce anxiolytic-like effects in animals, among other effects. PT-00114 is under development by Protagenic Therapeutics and Charles River Laboratories. As of August 2025, it is in phase 1/2 clinical trials for generalized anxiety disorder, major depressive disorder, opioid-related disorders, and PTSD and is in phase 1 trials for mood disorders. It is or was also under development for the treatment of other anxiety and depressive disorders as well as of impulse control disorders and neurodegenerative disorders, but no recent development has been reported for these indications.

isoelectric point (pH(I), pI) Also isoelectric pH. The pH at which a particular molecule, often a protein, carries no net electrical charge, i.e. at which it is electrically neutral in the statistical mean. The concentration of protons (H+) in the surrounding environment affects how readily molecules gain or lose protons and thus their electrical properties. When the environmental pH is greater than the molecule's pI, the molecule is negatively charged, and when the pH is less than the pI, it is positively charged. Isoelectric point is therefore important for determining the behavior of molecules exposed to electric fields, as in electrophoresis and ion chromatography. Proteins are least soluble at their isoelectric points because electrically neutral species do not repulse each other with electrostatic forces, such that they tend to aggregate and precipitate out of solution.

Several of Kissinger's own staff, most notably John Negroponte, were strongly opposed to him accepting this offer, saying Kissinger had given away more than he had obtained. In response to Negronponte's objections, Kissinger exploded in rage, accusing him of "nit-picking" and screamed at the top of his voice: "You don't understand. I want to meet their terms. I want to reach an agreement. I want to end this war before the election. It can be done and it will be done. What do you want us to do? Stay there forever?" Kissinger told Tho that he would go to Washington and Saigon to get the approval of Nixon and Thieu, and he expected the agreement to be signed on either 25 October or 26 October. On 12 October, Kissinger told Nixon: "Well, you've got three for three, Mr. President"—meaning trips to China and the Soviet Union plus a peace agreement for Vietnam. Even the fact that under the peace agreement, the United States was to pay reparations to North Vietnam in the form of economic aid was seen as a benefit by Nixon, who commented that this would be a way of forcing the Vietnamese Communists to admit to the economic failures of their system.

=== Oral lichen planus === Lichen planus (LP) is a T-cell-mediated autoimmune chronic disease of unknown etiology. Females have a three times higher prevalence than men. LP is characterized by T lymphocytes infiltration of the lower levels of epithelium, where they damage basal cells and cause apoptosis. The fetal microchimerism may trigger a fetus versus host reaction and therefore may play a role in the pathogenesis of autoimmune diseases including LP.

Sources: en.wikipedia.org

Supporting material

==== Weight loss ==== Prior to the MERIT study, numerous meta-analyses of studies on ESG report a total body weight loss of approximately 16% at one year. Excess weight loss was observed to be approximately 60% at one year. Weight loss reported from high volume community practices that have both expertise in ESG and robust longitudinal aftercare programs with dietitians have shown even greater outcomes, with total body weight loss approaching 30% and excess weight loss of 66% at one year.

=== Pirkle-type CSP === Pirkle and co-workers pioneered the development of a variety of CSPs based on charge-transfer complexation and simultaneous hydrogen bonding. These phases are also referred to as Brush-type CSPs. The Pirkle phases are based on aromatic π-acid (3,5-dinitrobenzoyI ring) and π- basic (naphthalene) derivative. In addition to π-π interaction sites, they have hydrogen-bonding and dipole-dipole interaction sites provided by an amide, urea or ester functionality. Strong three-point interaction, according to Dalgleish's model, enables enantioseparation. These phases are classified into π-electron-acceptor, π-electron-donor or π-electron acceptor-donor phase. A number of Pirkle-type CSPs are commercially available. They are used most often in the normal phase mode. The ionic form of the DNPBG (3,5-dinitrobenzoyl-phenylglycine) CSP has been successfully employed to achieve separation of racemic propranolol in biological fluid. Many compounds of pharmaceutical interest including enantiomers of naproxen and metoprolol has been separated using Pirkle CSP.

=== Mouse model === A mouse model of progeria exists, though in the mouse, the LMNA prelamin A is not mutated. Instead, ZMPSTE24, the specific protease that is required to remove the C-terminus of prelamin A, is missing. Both cases result in the buildup of farnesylated prelamin A on the nuclear membrane and in the characteristic nuclear LMNA blebbing. In 2020, BASE editing was used in a mouse model to target the LMNA gene mutation that causes the progerin protein instead of the healthy Lamin A while in 2023 a study designed a peptide that prevented progerin from binding to BubR1 which is known to regulate aging in mice.

== Boards of Directors == Bowman has served on the boards of directors of a number of companies in the areas of innovative technologies and the life sciences in addition to Dionex. From 1985 to 2007, Bowman served as a director of Molecular Devices Corporation, a supplier of bioanalytical measurement instruments. In 2006, he was appointed lead director of the board of Cell BioSciences, a privately held company engaged in protein research in the emerging area of nanoproteomics. He was appointed to the board of Solexa, Inc. in 2006. Solexa, which developed genome sequencing technology, was acquired in 2007 by Illumina, Inc., on whose board of directors Bowman now serves. Illumina develops tools for DNA, RNA, and protein analysis. A. Blaine Bowman joined Altera Corporation's board of directors as of July 30, 2012. Altera develops programmable logic devices.

=== Hertha BSC === The company took a 64.7% stake in Hertha BSC of the German Bundesliga in March 2023, after its sale by Lars Windhorst, who had been majority shareholder since 2019. Due to German football's 50+1 rule, 777 does not control the club. The company faced protests from Hertha's fans. In May 2024, The Athletic reported that fans were less antagonistic toward 777 at Hertha Berlin than at other clubs in their portfolio, partly due to the controversies and low points of Windhorst's ownership.

Sources: en.wikipedia.org

Frequently asked questions

How should the powder be stored?

Dry powder is best kept sealed, protected from light, and held at minus 20 degrees Celsius or below. Desiccant packaging helps limit moisture uptake because the material is hygroscopic. A sealed vial should be allowed to equilibrate to room temperature before opening to reduce condensation.

What limits shelf life in solution?

Hydrolysis of peptide bonds and deamidation of arginine and proline residues are the main degradation routes. Alkaline pH and higher temperatures accelerate both processes. Buffered, near-neutral solutions stored cold generally degrade more slowly than unbuffered ones.

Which purity test is most informative?

Reverse-phase chromatography gives the clearest single view of related impurities and truncated sequences. Mass spectrometry then confirms that the main peak carries the expected mass. Neither test detects enantiomeric impurities, which require a separate chiral assay.

How is a Selank sample checked for purity?

Reverse-phase HPLC is the usual method and gives a percentage purity value. Mass spectrometry then confirms the molecular mass. Together they provide a basic identity and purity profile for a lot.

Network